Arimidex (Anastrozole) 1 mg – 30 Tablets

Biochem Arimidex (Anastrozole) 1 mg – Oral Aromatase Inhibitor Tablets

Biochem Arimidex (Anastrozole) 1 mg – 30 Tablets is a product containing anastrozole, an orally active, nonsteroidal aromatase inhibitor used in certain hormone-sensitive breast cancer treatment settings.

Anastrozole belongs to the class of third-generation aromatase inhibitors. Its primary pharmacological action involves inhibiting the aromatase enzyme, which participates in the biosynthesis of estrogens from androgen precursors.

Anastrozole became commercially associated with the pharmaceutical brand name Arimidex. It has been used in oncology, particularly in the management of hormone receptor-positive breast cancer in postmenopausal women.

Unlike selective estrogen receptor modulators such as tamoxifen, anastrozole does not primarily block estrogen receptors. Instead, it reduces estrogen production by inhibiting aromatase activity.

Aromatase, also known as CYP19A1, is a cytochrome P450 enzyme responsible for converting androstenedione into estrone and testosterone into estradiol.

By inhibiting this enzyme, anastrozole reduces estrogen biosynthesis in tissues where aromatase is active.

Anastrozole is classified as a reversible, nonsteroidal aromatase inhibitor, distinguishing it from steroidal aromatase inactivators such as exemestane.

The compound is structurally unrelated to anabolic-androgenic steroids. It does not directly activate androgen receptors and is not itself an anabolic steroid.

Anastrozole has also been studied in selected male endocrine conditions. However, its established clinical indications, evidence, and safety considerations differ between populations, and its use for managing estrogen during anabolic steroid exposure is not an established indication.

Excessive estrogen suppression can produce clinically significant adverse effects, including reduced bone mineral density, joint symptoms, and disturbances in reproductive and metabolic health.

Arimidex is a pharmaceutical brand name associated with anastrozole. The use of this name in a Biochem product description does not establish that the product is authentic branded Arimidex or therapeutically equivalent to an authorized pharmaceutical preparation.

The Biochem Anastrozole product is described as containing 1 mg per tablet, with 30 tablets per package. This represents a total labeled active ingredient content of 30 mg per package.

The labeled strength does not constitute an individual dosage recommendation. Product identity, purity, excipients, and manufacturing specifications have not been independently verified.

1. Inhibits the Aromatase Enzyme

Anastrozole inhibits aromatase, the enzyme responsible for converting androgen precursors into estrogens.

Aromatase is expressed in several tissues, including adipose tissue, breast tissue, and other sites involved in peripheral estrogen production.

Inhibition of aromatase reduces the synthesis of estrone and estradiol.

2. Reduces Estrogen Biosynthesis

Anastrozole reduces estrogen production by interfering with the enzymatic conversion of androgens into estrogens.

This pharmacological effect is particularly relevant in postmenopausal women, whose estrogen production depends substantially on peripheral aromatization.

The magnitude of estrogen suppression depends on physiological characteristics, treatment conditions, and individual response.

3. Has Established Applications in Hormone-Sensitive Breast Cancer

Anastrozole has been used in the treatment of selected hormone receptor-positive breast cancers in postmenopausal women.

Reducing estrogen production can decrease hormonal stimulation of estrogen-dependent breast cancer cells.

Its clinical application requires appropriate diagnosis, treatment selection, and medical supervision.

4. Functions as a Nonsteroidal Aromatase Inhibitor

Anastrozole is chemically distinct from steroidal aromatase inhibitors such as exemestane.

It inhibits aromatase reversibly rather than permanently inactivating the enzyme.

This distinction is relevant to its pharmacological classification and mechanism of action.

5. Does Not Directly Block Estrogen Receptors

Anastrozole does not function primarily as an estrogen receptor antagonist.

Instead, it reduces the production of estrogen through enzyme inhibition.

This distinguishes its mechanism from selective estrogen receptor modulators such as tamoxifen.

6. Influences Hormonal Regulation

Estrogens contribute to bone metabolism, reproductive physiology, cardiovascular regulation, and other biological functions in both women and men.

Reducing estrogen concentrations can alter these physiological processes.

In men, aromatase inhibition may affect testosterone and estradiol concentrations, but the clinical consequences vary, and routine use without a defined medical indication is not established.

7. Has Important Bone, Musculoskeletal, and Cardiovascular Safety Considerations

Anastrozole can reduce bone mineral density and increase fracture risk in susceptible individuals.

Other reported adverse effects include joint pain, hot flashes, fatigue, nausea, headache, and changes in cholesterol measurements.

Its effects on cardiovascular risk require consideration of the individual's underlying condition and other risk factors.

Anastrozole carries clinically important risks, including bone loss, fractures, musculoskeletal symptoms, hot flashes, and possible cardiovascular complications. Serious hypersensitivity reactions and liver-related adverse effects have also been reported. It should not be used during pregnancy because fetal harm may occur. Its use in premenopausal women without appropriate ovarian suppression is generally unsuitable for standard breast cancer indications.

The 1 mg tablet strength describes the labeled quantity of anastrozole per tablet. It does not establish an appropriate dose, administration frequency, treatment duration, or individual medical indication.

Anastrozole is an orally active aromatase inhibitor whose principal mechanism involves reducing estrogen biosynthesis through reversible inhibition of CYP19A1.

Its pharmacological activity differs from anabolic-androgenic steroids because it does not directly activate androgen receptors.

Step 1 – Oral Administration and Gastrointestinal Absorption

Anastrozole is administered orally in established pharmaceutical formulations.

Following administration, it is absorbed through the gastrointestinal tract and enters systemic circulation.

Food may influence the rate of absorption, but it does not substantially alter the overall extent of absorption.

Step 2 – Distribution to Tissues Expressing Aromatase

Following absorption, anastrozole distributes throughout the body and reaches tissues where aromatase is expressed.

These include adipose tissue and other peripheral sites involved in estrogen biosynthesis.

Step 3 – Reversible Inhibition of Aromatase

Anastrozole interacts with the aromatase enzyme and inhibits its catalytic activity.

This reduces the conversion of androstenedione into estrone and testosterone into estradiol.

Step 4 – Reduction of Estrogen-Dependent Signaling

By decreasing estrogen production, anastrozole can reduce stimulation of estrogen-dependent cellular pathways.

This mechanism underlies its established role in selected hormone receptor-positive breast cancer treatment settings.

Excessive estrogen suppression may also produce undesirable effects on bone, joints, and other tissues.

Step 5 – Hepatic Metabolism and Elimination

Anastrozole undergoes hepatic metabolism through pathways including N-dealkylation, hydroxylation, and glucuronidation.

Metabolites and unchanged drug are eliminated through excretory pathways.

Its terminal elimination half-life is approximately 50 hours, although individual pharmacokinetic characteristics may vary.

Anastrozole has been manufactured in oral solid-dose pharmaceutical formulations, including 1 mg tablets.

The Biochem Arimidex 1 mg oral tablet presentation is described by the following characteristics:

• Anastrozole as the labeled active ingredient.
• A labeled strength of 1 mg per tablet.
• A package quantity of 30 tablets.
• A total labeled active ingredient content of 30 mg.
• Nonsteroidal aromatase inhibitor classification.
• Third-generation aromatase inhibitor pharmacology.
• Reversible inhibition of CYP19A1.
• Reduction of estrone and estradiol biosynthesis.
• No direct anabolic-androgenic steroid activity.
• No primary estrogen receptor antagonism.
• Oral solid-dose pharmaceutical presentation.
• Established medical applications in selected breast cancer settings.
• Hepatic metabolism.
• An approximate elimination half-life of 50 hours.
• Potential effects on bone mineral density.
• Musculoskeletal and cardiovascular safety considerations.
• Excipients selected for tablet manufacturing and stability.
• Formulation-dependent dissolution and absorption.
• Packaging intended to protect tablets from environmental exposure.
• Product identity, purity, and content uniformity requiring analytical verification.

The precise formulation, excipient composition, tablet appearance, and manufacturing specifications of Biochem Arimidex 1 mg have not been confirmed.

The presence of 30 tablets does not establish an appropriate treatment duration or individual prescription. The Biochem product should not be represented as authentic branded Arimidex or as an approved interchangeable generic without independent verification.

United States

Biochem Arimidex 1mg, Biochem Anastrozole 1mg, Arimidex 30 tablets, Anastrozole 30 tablets, Arimidex United States, Anastrozole oral tablets, Anastrozole aromatase inhibitor, Arimidex pharmacology, Anastrozole mechanism of action, Arimidex CYP19A1 inhibition, Anastrozole estrogen biosynthesis, Arimidex molecular formula, Anastrozole chemical structure, Arimidex oral formulation, Anastrozole breast cancer treatment, Arimidex bone health considerations, Anastrozole safety information, Arimidex tablet specifications.

Canada

English: Biochem Arimidex 1mg Canada, Anastrozole 1mg Canada, Arimidex 30 tablets Canada, Anastrozole oral tablets, Arimidex aromatase inhibitor, Anastrozole properties, Arimidex pharmacology, Anastrozole CYP19A1, Arimidex estrogen suppression, Anastrozole molecular structure, Arimidex mechanism of action, Anastrozole breast cancer treatment, Arimidex safety information.

French: Biochem Arimidex 1 mg Canada, anastrozole 1 mg, Arimidex 30 comprimés, inhibiteur de l'aromatase, propriétés de l'anastrozole, pharmacologie de l'Arimidex, enzyme CYP19A1, biosynthèse des œstrogènes, structure moléculaire, traitement du cancer du sein hormonosensible, mécanisme d'action de l'anastrozole, composition des comprimés, informations de sécurité.

United Kingdom

Biochem Arimidex 1mg UK, Anastrozole 1mg UK, Arimidex 30 tablets, Anastrozole oral tablets, Arimidex aromatase inhibitor, Anastrozole pharmacology, Arimidex CYP19A1 inhibition, Anastrozole oestrogen biosynthesis, Arimidex molecular composition, Anastrozole mechanism of action, Arimidex breast cancer therapy, Anastrozole bone health effects, Arimidex tablet formulation.

Germany

Biochem Arimidex 1 mg Deutschland, Anastrozol 1 mg, Arimidex 30 Tabletten, Aromatasehemmer, Anastrozol Eigenschaften, Arimidex Wirkungsmechanismus, Anastrozol Zusammensetzung, CYP19A1 Hemmung, Östrogenbiosynthese, hormonrezeptorpositiver Brustkrebs, Anastrozol Molekülstruktur, Leberstoffwechsel, Knochendichte, Arimidex Sicherheitsinformationen.

France

Biochem Arimidex 1 mg France, anastrozole 1 mg, Arimidex 30 comprimés, inhibiteur de l'aromatase, propriétés de l'anastrozole, mécanisme d'action de l'Arimidex, composition de l'anastrozole, inhibition du CYP19A1, biosynthèse des œstrogènes, cancer du sein hormonodépendant, structure moléculaire, métabolisme hépatique, densité minérale osseuse, informations de sécurité.

Spain

Biochem Arimidex 1 mg España, anastrozol 1 mg, Arimidex 30 tabletas, inhibidor de la aromatasa, propiedades del anastrozol, cómo funciona el Arimidex, composición del anastrozol, inhibición de CYP19A1, biosíntesis de estrógenos, cáncer de mama hormonodependiente, estructura molecular, metabolismo hepático, densidad mineral ósea, mecanismo de acción del Arimidex, información de seguridad.

Italy

Biochem Arimidex 1 mg Italia, anastrozolo 1 mg, Arimidex 30 compresse, inibitore dell'aromatasi, proprietà dell'anastrozolo, meccanismo d'azione dell'Arimidex, composizione dell'anastrozolo, inibizione del CYP19A1, biosintesi degli estrogeni, carcinoma mammario ormonosensibile, struttura molecolare, metabolismo epatico, densità minerale ossea, informazioni di sicurezza.

Portugal

Biochem Arimidex 1 mg Portugal, anastrozol 1 mg, Arimidex 30 comprimidos, inibidor da aromatase, propriedades do anastrozol, mecanismo de ação do Arimidex, composição do anastrozol, inibição do CYP19A1, biossíntese de estrogénios, cancro da mama hormonossensível, estrutura molecular, metabolismo hepático, densidade mineral óssea, informações de segurança.

Netherlands

Biochem Arimidex 1 mg Nederland, anastrozol 1 mg, Arimidex 30 tabletten, aromataseremmer, eigenschappen van anastrozol, werkingsmechanisme Arimidex, samenstelling van anastrozol, CYP19A1 remming, oestrogeenbiosynthese, hormoongevoelige borstkanker, moleculaire structuur, levermetabolisme, botmineraaldichtheid, veiligheidsinformatie.

Belgium

Biochem Arimidex 1 mg Belgium, Arimidex 1 mg België, anastrozol 1 mg, anastrozole 1 mg, Arimidex 30 tabletten, Arimidex 30 comprimés, aromataseremmer, inhibiteur de l'aromatase, eigenschappen van anastrozol, propriétés de l'anastrozole, CYP19A1 remming, inhibition du CYP19A1, oestrogeenbiosynthese, biosynthèse des œstrogènes, botmineraaldichtheid, densité minérale osseuse.

Switzerland

Biochem Arimidex 1 mg Switzerland, Arimidex 1 mg Schweiz, Arimidex 1 mg Suisse, Anastrozol 1 mg, anastrozole 1 mg, Arimidex 30 Tabletten, Arimidex 30 comprimés, Aromatasehemmer, inhibiteur de l'aromatase, Anastrozol Eigenschaften, propriétés de l'anastrozole, CYP19A1 Hemmung, inhibition du CYP19A1, Östrogenbiosynthese, biosynthèse des œstrogènes.

Austria

Biochem Arimidex 1 mg Österreich, Anastrozol 1 mg, Arimidex 30 Tabletten, Aromatasehemmer, Anastrozol Eigenschaften, Arimidex Wirkungsmechanismus, CYP19A1 Hemmung, Östrogenbiosynthese, hormonrezeptorpositiver Brustkrebs, Molekülstruktur, Leberstoffwechsel, Knochendichte, Anastrozol Zusammensetzung, Sicherheitsinformationen.

Sweden

Biochem Arimidex 1 mg Sverige, anastrozol 1 mg, Arimidex 30 tabletter, aromatashämmare, anastrozol egenskaper, Arimidex verkningsmekanism, CYP19A1 hämning, östrogenbiosyntes, hormonreceptorpositiv bröstcancer, molekylstruktur, levermetabolism, bentäthet, Arimidex farmakologi, säkerhetsinformation.

Norway

Biochem Arimidex 1 mg Norge, anastrozol 1 mg, Arimidex 30 tabletter, aromatasehemmer, anastrozol egenskaper, Arimidex virkningsmekanisme, CYP19A1 hemming, østrogenbiosyntese, hormonreseptorpositiv brystkreft, molekylstruktur, levermetabolisme, bentetthet, Arimidex farmakologi, sikkerhetsinformasjon.

Denmark

Biochem Arimidex 1 mg Danmark, anastrozol 1 mg, Arimidex 30 tabletter, aromatasehæmmer, anastrozol egenskaber, Arimidex virkningsmekanisme, CYP19A1 hæmning, østrogenbiosyntese, hormonreceptorpositiv brystkræft, molekylstruktur, levermetabolisme, knoglemineraltæthed, Arimidex farmakologi, sikkerhedsinformation.

Finland

Biochem Arimidex 1 mg Suomi, anastrotsoli 1 mg, Arimidex 30 tablettia, aromataasin estäjä, anastrotsolin ominaisuudet, Arimidex vaikutusmekanismi, CYP19A1 entsyymin esto, estrogeenin biosynteesi, hormonireseptoripositiivinen rintasyöpä, molekyylirakenne, maksametabolia, luuntiheys, Arimidex farmakologia, turvallisuustiedot.

Poland

Biochem Arimidex 1 mg Polska, anastrozol 1 mg, Arimidex 30 tabletek, inhibitor aromatazy, właściwości anastrozolu, mechanizm działania Arimidex, skład anastrozolu, hamowanie CYP19A1, biosynteza estrogenów, hormonozależny rak piersi, struktura molekularna, metabolizm wątrobowy, gęstość mineralna kości, informacje o bezpieczeństwie.

Czech Republic

Biochem Arimidex 1 mg Česko, anastrozol 1 mg, Arimidex 30 tablet, inhibitor aromatázy, vlastnosti anastrozolu, mechanismus účinku Arimidex, složení anastrozolu, inhibice CYP19A1, biosyntéza estrogenů, hormonálně pozitivní karcinom prsu, molekulární struktura, jaterní metabolismus, kostní minerální hustota, bezpečnostní informace.

Romania

Biochem Arimidex 1 mg România, anastrozol 1 mg, Arimidex 30 comprimate, inhibitor de aromatază, proprietăți anastrozol, mecanism de acțiune Arimidex, compoziția anastrozolului, inhibarea CYP19A1, biosinteza estrogenilor, cancer mamar hormonodependent, structură moleculară, metabolism hepatic, densitate minerală osoasă, informații de siguranță.

Greece

Biochem Arimidex 1 mg Ελλάδα, αναστροζόλη 1 mg, Arimidex 30 δισκία, αναστολέας αρωματάσης, ιδιότητες αναστροζόλης, μηχανισμός δράσης Arimidex, σύνθεση αναστροζόλης, αναστολή CYP19A1, βιοσύνθεση οιστρογόνων, ορμονοευαίσθητος καρκίνος μαστού, μοριακή δομή, ηπατικός μεταβολισμός, οστική πυκνότητα, πληροφορίες ασφάλειας.

Ireland

Biochem Arimidex 1mg Ireland, Anastrozole 1mg Ireland, Arimidex 30 tablets, Anastrozole oral tablets, Arimidex aromatase inhibitor, Anastrozole pharmacology, Arimidex CYP19A1 inhibition, Anastrozole oestrogen biosynthesis, Arimidex molecular composition, Anastrozole mechanism of action, Arimidex breast cancer treatment, Anastrozole bone health considerations, Arimidex tablet formulation.

Colombia

Biochem Arimidex 1 mg Colombia, anastrozol 1 mg Colombia, Arimidex 30 tabletas, inhibidor de la aromatasa, propiedades del anastrozol, cómo funciona el Arimidex, farmacología del anastrozol, composición del Arimidex, inhibición de CYP19A1, biosíntesis de estrógenos, cáncer de mama hormonodependiente, estructura molecular, metabolismo hepático, densidad mineral ósea, mecanismo de acción del Arimidex, información de seguridad.

Argentina

Biochem Arimidex 1 mg Argentina, anastrozol 1 mg Argentina, Arimidex 30 comprimidos, inhibidor de la aromatasa, propiedades del anastrozol, qué es el Arimidex, cómo actúa el anastrozol, farmacología del Arimidex, inhibición de CYP19A1, biosíntesis de estrógenos, cáncer de mama hormonodependiente, estructura molecular, metabolismo hepático, densidad mineral ósea, composición del Arimidex.

México

Biochem Arimidex 1 mg México, anastrozol 1 mg México, Arimidex 30 tabletas, inhibidor de la aromatasa, propiedades del anastrozol, para qué se utiliza el Arimidex, cómo funciona el anastrozol, farmacología del Arimidex, inhibición de CYP19A1, biosíntesis de estrógenos, cáncer de mama con receptores hormonales positivos, estructura molecular, metabolismo hepático, densidad mineral ósea, mecanismo de acción del Arimidex.

Perú

Biochem Arimidex 1 mg Perú, anastrozol 1 mg Perú, Arimidex 30 tabletas, inhibidor de la aromatasa, propiedades del anastrozol, qué es el anastrozol, cómo funciona el Arimidex, farmacología del Arimidex, inhibición de CYP19A1, biosíntesis de estrógenos, cáncer de mama hormonodependiente, estructura molecular, metabolismo hepático, densidad mineral ósea, composición del Arimidex.

Venezuela

Biochem Arimidex 1 mg Venezuela, anastrozol 1 mg Venezuela, Arimidex 30 tabletas, inhibidor de la aromatasa, propiedades del anastrozol, qué es el Arimidex, cómo actúa el anastrozol, farmacología del Arimidex, inhibición de CYP19A1, biosíntesis de estrógenos, cáncer de mama hormonodependiente, estructura molecular, metabolismo hepático, densidad mineral ósea, composición del Arimidex.

Ecuador

Biochem Arimidex 1 mg Ecuador, anastrozol 1 mg Ecuador, Arimidex 30 tabletas, inhibidor de la aromatasa, propiedades del anastrozol, para qué se utiliza el Arimidex, cómo funciona el anastrozol, farmacología del Arimidex, inhibición de CYP19A1, biosíntesis de estrógenos, cáncer de mama hormonodependiente, estructura molecular, metabolismo hepático, densidad mineral ósea, composición del Arimidex, mecanismo de acción del anastrozol, información de seguridad.

Biochem Arimidex (Anastrozole) 1mg | 30 Tablets | Aromatase Inhibitor

Learn about Biochem Arimidex 1mg, a 30-tablet product labeled as containing anastrozole, a nonsteroidal aromatase inhibitor that reduces estrogen biosynthesis through CYP19A1 inhibition, with established applications in selected hormone-sensitive breast cancer settings.

Biochem Arimidex (Anastrozol) 1mg | 30 Tabletas | Inhibidor de la Aromatasa

Conoce Biochem Arimidex 1mg, una presentación de 30 tabletas etiquetada como anastrozol, un inhibidor no esteroideo de la aromatasa que reduce la biosíntesis de estrógenos mediante la inhibición de CYP19A1, utilizado en determinados tratamientos del cáncer de mama hormonodependiente.

biochem-arimidex-anastrozole-1mg-30-tablets

biochem-arimidex-anastrozol-1mg-30-tabletas

Biochem Arimidex Anastrozole 1mg package labeled as containing 30 oral tablets of anastrozole, a third-generation nonsteroidal aromatase inhibitor associated with reversible CYP19A1 inhibition and reduced estrogen biosynthesis.

Biochem Arimidex Anastrozol 1mg presentación etiquetada como 30 tabletas orales de anastrozol, un inhibidor no esteroideo de la aromatasa de tercera generación asociado con la inhibición reversible de CYP19A1 y la reducción de la biosíntesis de estrógenos.